LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global nuclear imaging market is expected to grow at a CAGR of more than 6% during the forecast period.

This research report titled ‘Global Nuclear Imaging Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

The global nuclear imaging market has a great potential to grow in the coming future. Currently, the nuclear imaging market is dominated by the Americas followed by EMEA and APAC. In the Americas, North America dominated the market hold the largest market share followed by Europe. The factors contributing the growth in this region are increasing the availability of nuclear imaging centers, rapid and growing geriatric population coupled with cardiac disorders, and high prevalence of cancers. Also, growing technological advances in instruments and increasing demand for non-invasive diagnostic imaging techniques contribute to the growth of the global nuclear imaging market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio’s healthcare and life sciences research analysts categorize the global nuclear imaging market into the following segments by product. They are:

Standalone PET nuclear imaging
Standalone SPECT nuclear imaging
Hybrid nuclear imaging
Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Standalone PET nuclear imaging

Positron emission tomography (PET) is a functional non-invasive imaging technique, which involves the use of radioactive pharmaceuticals injected into the body (oral, inhaled or intravenously administered) that enables visualization of metabolic processes of the organs. Standalone PET systems have sensitive detector panels to capture the gamma rays which comes from the body and create a 3D computed tomography images of the tracer concentrations in the body.

According to Barath Palada, a lead medical imaging research analyst from Technavio, “The standalone PET nuclear imaging used to diagnose cancers, heart diseases, endocrine, neurological and many other abnormalities in the body. PET scanners also assess cellular metabolic functions accurately which helps the doctor evaluate the functioning of the organ or tissues. PET technology can deliver high-quality images and, hence, is used for both medical and research purposes.”

Molecular Imaging Homepage